Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Spinal cord injury
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseSpinal cord injuryComplete transectionC57Bl/6femalesubcutaneous osmotic minipump (Alzet 1007D)1 mg/kg/day in 0.9% salinePump implanted at the time of injury
Model: Complete spinal cord transection between T8 and T9 vertebrae after laminectomy under isoflurane; bladders manually voided twice daily; tissue collected 3 days after injury
MitoTempo lowered nitrotyrosine, reduced or eliminated aberrant mitochondrial inclusions and increased autolysosomes, although apoptotic markers and DRP1 only trended towards normal.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.